On 27 December 2012, the Belgian federal government introduced
two draft bills aimed at reforming Belgian competition law. These
bills are expected to be adopted in February 2013 but will not
enter into force before 1 April 2013 at the earliest.
While the draft legislation does not affect the substance of the
Belgian competition rules on anti-competitive agreements, abuse of
a dominant position and merger control, it introduces a number of
important procedural reforms.
Most notably, the bills introduce the possibility for the
Competition Authority to fine individuals who were involved in
"hardcore" infringements of competition law, such as
price-fixing cartels. In return, these individuals also become
eligible for immunity from fines as part of the leniency
The draft legislation also brings about a significant reform of
the Belgian Competition Authority ("BCA"), which will be
set up as a single, independent authority but will be divided in
four distinct divisions with separate tasks. The BCA will consist
of (i) a President; (ii) a Competition College; (iii) a Management
Committee; and (iv) a College of Prosecutors headed by a Chief
In order to ensure that the new Competition Authority remains
fully independent, the draft legislation puts an end to the current
powers of the Council of Ministers to overrule a merger control
prohibition decision adopted by the Competition Authority (a power
which the Council of Ministers never made use of).
The draft legislation also improves the Competition
Authority's decision-making process, codifies the existing
leniency procedure, introduces a settlement procedure and provides
for more efficient interim measure procedures. In line with a
recent ruling of the Belgian Constitutional Court (see VBB on
Competition Law, Volume 2012, No. 12, available at
www.vbb.com), the draft legislation also provides that
antitrust fines are not tax deductible.
Finally, the draft legislation broadens the powers of the
existing Price Observatory, which will be in charge of the
detection of any "problems regarding prices or margins,
abnormal pricing developments or structural market problems".
Any finding of such supposed pricing anomalies will be transmitted
to the Competition Authority for further review. In addition, the
government will be given the power to take structural measures
The content of this article is intended to provide a general
guide to the subject matter. Specialist advice should be sought
about your specific circumstances.
To print this article, all you need is to be registered on Mondaq.com.
Click to Login as an existing user or Register so you can print this article.
In this section, we give a factual overview of a significant case development at EU level, and then provide a more detailed analysis of the important substantive and procedural developments addressed in this case.
Sayenko Kharenko's antitrust team has provided legal assistance in obtaining merger clearance with the Antimonopoly Committee of Ukraine (the "AMC") for the EUR 22.8 billion acquisition of Sanofi's animal health (AH) business ("Merial") by Boehringer Ingelheim through an asset swap in exchange for Boehringer Ingelheim's consumer healthcare (CHC) business.
Some comments from our readers… “The articles are extremely timely and highly applicable” “I often find critical information not available elsewhere” “As in-house counsel, Mondaq’s service is of great value”
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).